IXC

0.00%

6.6¢ invex therapeutics ltd

Ann: Invex Granted European Orphan Drug Designation for TBI, page-61

First 61 Last

Share
Profile

Follow
SSilverstein

795 Posts.

45

25/06/23

22:09

Post #: 68461583
Share

Originally posted by arkangel256: ↑

Correct. Tropical Diseases is a special case for which PRV apply for adults.

To get technical - if we're talking about Priority Review Vouchers here, then Reon1 is correct in stating that a reformulation will not get a Priority Review Voucher. This is because the active ingredient needs to be unique. Neuren's trofinetide is an example.

However, Invex is not seeking to exploit Priority Review Vouchers. It is going down a completely different pathway. It is utilising the Orphan Drug Designation pathway for which reformulation and repurposing is within scope. There is no stipulation preventing one drug from earning more than one orphan drug approval.

It is unlikely that Invex will seek to simply re-use Presendin in TBI. The active ingredient is a synthetic form of Exendin-4, for which Invex bought the rights from Astrazeneca for neurological indications. They reformulated this to 'Presendin' to match the disease characteristics of the IIH condition.

Invex will likely undergo a proof of concept study(Phase 2) for TBI, for which the final reformulation they will seek to get approval for will be different to Presendin for IIH, as they will need to use a reformulation with a different pharmacokinetic profile to be effective in TBI. We know in 2020, Invex raised capital post Phase II results, for a proof of study in a 2nd indication. Three years later, we finally know that it is for Traumatic Brain Injury, for which they're funded to complete.

Invex's strategy is simple. Achieve success in the Phase 3 for IIH. Have a pipeline of proof of concept studies in other indications e.g. TBI. And then sell to Big Pharma who will pay several multiples for the next big blockbuster drug.

Expand

Very well said. Thanks for clarifying

IXC Price at posting: 60.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ASX hits all time high out the gate on Friday trades following bullish US inflation data

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

There are more pages in this discussion • 14 more messages in this thread...

First 61 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 6.6¢		Change 0.000(0.00%)		Mkt cap ! $4.960M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	100000	6.2¢

Sellers (Offers)

Price($)	Vol.	No.
6.8¢	10000	1

View Market Depth

No.	Vol.	Price($)
1	100000	0.062
1	15500	0.061
1	150000	0.060
1	100000	0.052
1	60001	0.041

Price($)	Vol.	No.
0.068	10000	1
0.069	16500	1
0.070	40000	1
0.076	888	1
0.083	4000	1

Last trade - 16.12pm 12/07/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

Ann: Invex Granted European Orphan Drug Designation for TBI, page-61

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Invex Granted European Orphan Drug Designation for TBI, page-61

Top Stories

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News